The Color of Stem Cells
By Josef Tayag,
The Greenlining Institute
| 09. 09. 2005
Why the benefits of stem cell research might not be for people like me.
After losing half of one of my lungs to tuberculosis while
volunteering in the Andes last year, I assumed that life would
just never be the same again. By this I meant that the flight
of stairs to my apartment would always seem twice as long and
that I would have to give up things I enjoyed like taking long
runs on Sunday mornings.
However, the promise of therapeutic treatments derived from
stem cell research gives individuals like me a hope for normalcy.
Yet, as an immigrant from a low-income family, I can’t
stop from cringing at the thought that the low-income and marginalized
communities of the state still have no explicit guarantee of
access to the promised 'cures' of Prop. 71—much less to
adequate health care in general.
Last Friday, the Independent Citizen’s Oversight Committee
(ICOC) allocated a little over $39 million to prestigious research
institutions like UCLA, UC Berkeley, Stanford, USC, and Cal
Tech among others. Yet, it’s unclear from perusing through
many of their grant proposals just how much focus these research
institutions will give to communities...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...